Lonza Group Ltd. Introduces New L7 PBMC Reprogramming Bundle For The Simple, Rapid And Reliable Generation Of hiPSCs From PBMCs
Walkersville, MD, USA, 11 June 2015 – Lonza has today released the latest addition to its L7™ hPSC System, a robust, streamlined and comprehensive platform for the generation of human induced pluripotent stem cells (hiPSCs) and the maintenance of stem cells from a variety of sources. The new L7™ PBMC Reprogramming Bundle slots seamlessly into the existing L7™ workflow to enable researchers to reprogram peripheral blood mononuclear cells (PBMCs) for use in downstream experiments. Because of its series of reagents and protocols optimized for working specifically with PBMCs, the new bundle makes it easier and faster to generate hiPSCs. The L7™ hPSC System offers a complete workflow that combines primary cells, reprogramming kits, transfection tools and culturing media, along with a matrix, passaging solution and cryosolution. As such, it streamlines the reprogramming of somatic cells to generate hiPSCs, as well as supporting the ongoing maintenance and utilization of human embryonic stem cells (hESCs) and hiPSCs.
Newly Enhanced Reagents for Reprogramming PBMCs
The L7™ PBMC Reprogramming Bundle contains a number of newly enhanced components. These include the new L7™ PBMC Priming-Recovery Kit, which primes PBMCs prior to reprogramming and provides optimal recovery of the hiPSCs following the delivery of reprogramming vectors using Lonza’s well-established 4D-Nucleofector™ technology. The new bundle also contains PBMC-specific reprogramming enhancers for superior results. Lastly, Lonza also offers a source of human PBMCs for researchers to use as a positive control donor during their reprogramming experiments.
Once the PBMCs have undergone the reprogramming process, they are cultured and expanded using the novel L7™ hPSC Culture System, which includes the L7™ hPSC Matrix, Basal Medium and Supplement. To assist with passaging these cells, the L7™ hPSC Passaging Solution offers non-enzymatic cell detachment, without the need for mechanical manipulation. This user-friendly method has been specifically formulated to protect valuable cell lines. Lastly, the L7™ hPSC Cryosolution enables the efficient recovery of frozen cells after storage. The entire L7™ System is xeno-free, fully defined and proven to support the long-term culture and pluripotency of PSCs. Importantly, the hiPSCs created using the new L7™ PBMC Reprogramming Bundle can efficiently differentiate into all three germ layers and are ready for use across a wide range of applications, from basic research and disease modeling, through to drug development and regenerative medicine.
Dr. Minh Hong, Marketing Manager at Lonza Bioscience Solutions, commented: “Lonza is a leading supplier of primary and stem cell solutions for use in life science laboratories, and we’ve applied our experience into the L7™ hiPSC Reprogramming and hPSC Culture System. The new L7™ PBMC Reprogramming Bundle is a powerful addition to the L7™ portfolio and is part of our ongoing commitment to develop the best tools for stem cell researchers. Because of its robust performance, optimized workflow and increased flexibility, it is an ideal choice for researchers looking to generate, culture and eventually differentiate their hPSCs.”
For more information on the L7™ hiPSC Reprogramming and hPSC Culture System, including the new L7™ PBMC Reprogramming Bundle, please visit www.lonza.com/L7.
About Lonza Pharma&Biotech ?? Bioscience Solutions
Lonza provides the pharma market with the tools life science researchers use to develop and test therapeutics, from basic research to final product release. Lonza’s bioscience products and services range from cell culture and discovery technologies for research, to quality control tests and software to ensure product quality. Lonza Bioscience Solutions serves research customers worldwide in pharmaceutical, biopharmaceutical, biotechnology and personal care companies, as well as academic and government research institutions. The company delivers physiologically relevant cell biology solutions, and complete solutions for rapid microbiology. Primary brands include BioWhittaker™, Clonetics™, FlashGel™, MetaPhor™, MycoAlert™, Nucleofection™, NuSieve™, PAGEr™, Poietics™ and SeaKem®.
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 employees worldwide. The company generated sales of about CHF 3.64 billion in 2014 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.
Help employers find you! Check out all the jobs and post your resume.
Newly Enhanced Reagents for Reprogramming PBMCs
The L7™ PBMC Reprogramming Bundle contains a number of newly enhanced components. These include the new L7™ PBMC Priming-Recovery Kit, which primes PBMCs prior to reprogramming and provides optimal recovery of the hiPSCs following the delivery of reprogramming vectors using Lonza’s well-established 4D-Nucleofector™ technology. The new bundle also contains PBMC-specific reprogramming enhancers for superior results. Lastly, Lonza also offers a source of human PBMCs for researchers to use as a positive control donor during their reprogramming experiments.
Once the PBMCs have undergone the reprogramming process, they are cultured and expanded using the novel L7™ hPSC Culture System, which includes the L7™ hPSC Matrix, Basal Medium and Supplement. To assist with passaging these cells, the L7™ hPSC Passaging Solution offers non-enzymatic cell detachment, without the need for mechanical manipulation. This user-friendly method has been specifically formulated to protect valuable cell lines. Lastly, the L7™ hPSC Cryosolution enables the efficient recovery of frozen cells after storage. The entire L7™ System is xeno-free, fully defined and proven to support the long-term culture and pluripotency of PSCs. Importantly, the hiPSCs created using the new L7™ PBMC Reprogramming Bundle can efficiently differentiate into all three germ layers and are ready for use across a wide range of applications, from basic research and disease modeling, through to drug development and regenerative medicine.
Dr. Minh Hong, Marketing Manager at Lonza Bioscience Solutions, commented: “Lonza is a leading supplier of primary and stem cell solutions for use in life science laboratories, and we’ve applied our experience into the L7™ hiPSC Reprogramming and hPSC Culture System. The new L7™ PBMC Reprogramming Bundle is a powerful addition to the L7™ portfolio and is part of our ongoing commitment to develop the best tools for stem cell researchers. Because of its robust performance, optimized workflow and increased flexibility, it is an ideal choice for researchers looking to generate, culture and eventually differentiate their hPSCs.”
For more information on the L7™ hiPSC Reprogramming and hPSC Culture System, including the new L7™ PBMC Reprogramming Bundle, please visit www.lonza.com/L7.
About Lonza Pharma&Biotech ?? Bioscience Solutions
Lonza provides the pharma market with the tools life science researchers use to develop and test therapeutics, from basic research to final product release. Lonza’s bioscience products and services range from cell culture and discovery technologies for research, to quality control tests and software to ensure product quality. Lonza Bioscience Solutions serves research customers worldwide in pharmaceutical, biopharmaceutical, biotechnology and personal care companies, as well as academic and government research institutions. The company delivers physiologically relevant cell biology solutions, and complete solutions for rapid microbiology. Primary brands include BioWhittaker™, Clonetics™, FlashGel™, MetaPhor™, MycoAlert™, Nucleofection™, NuSieve™, PAGEr™, Poietics™ and SeaKem®.
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 employees worldwide. The company generated sales of about CHF 3.64 billion in 2014 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.
Help employers find you! Check out all the jobs and post your resume.